[1] 吴金民,赵昌峻.实用肿瘤治疗手册[M].浙江:浙江科学技术出版社, 2000:1-3.[2] 王银松,李英霞,宋妮,等.靶向抗肿瘤药物甲氨喋呤—琥珀酰壳聚糖缀合物的制备及其体外稳定性的初步探讨[J].高等学校化学学报,2003,24(11):2103-2106.[3] 黄园,袁芳,张志荣.肿瘤靶向给药系统的研究进展[J].华西药学杂志,2006,21(6):566-569.[4] 许向阳,周建平,李玲,等.多柔比星壳聚糖聚合物胶束的制备及其在小鼠体内的组织分布[J].药学学报,2008,43(7):743-748.[5] Mansouri S, Cuie Y, Winnik F, et al. Characterization of folate-chitosan-DNA nanoparticles for gene therapy. Biomaterials. 2006;27(9):2060-2065. [6] Nettles DL, Elder SH, Gilbert JA. Potential use of chitosan as a cell scaffold material for cartilage tissue engineering. Tissue Eng. 2002;8(6):1009-1016. [7] 中国知网.中国学术期刊总库[DB/OL].2012-09-16. https://www.cnki.net.[8] 王红昌.以壳聚糖及其衍生物为载体的高分子抗肿瘤药物的制备[D].江苏:苏州大学,2007:1-72.[9] 欧阳海燕.壳聚糖衍生物与抗肿瘤药物偶合物的制备及其活性研究[D].江苏:苏州大学,2009:1-59.[10] 冯炜玮.去甲斑蝥素-羟丙基壳聚糖纳米粒的制备及其体外抗肿瘤性能研究[D].山东:山东理工大学,2012:1-60.[11] 王钦.去甲斑蝥素N-乳糖酰壳聚糖纳米粒的制备与性质研究[D].江苏:苏州大学,2009:1-66.[12] 张静.油酰壳聚糖纳米粒作为抗肿瘤药物载体的研究[D].山东:中国海洋大学,2010:1-132.[13] 陈红丽.多糖修饰的PLGA纳米粒作为抗肿瘤药物载体的研究[D].北京:北京协和医学院,2009:1-108.[14] 谢永美.N,O-羧甲基壳聚糖-阿霉素偶联物的合成及其性质研究[D].四川:四川大学,2006:1-53.[15] 郭立文.表柔比星壳聚糖隐形纳米粒的制备及其抗肿瘤活性的检测[D].广东:南方医科大学,2009:1-46.[16] 杨静.负载表柔比星壳聚糖微球的制备联合微波消融治疗小鼠皮下肝移植瘤疗效观察[D].广东:南方医科大学,2010:1-42.[17] 王媛媛.抗肿瘤药物(5-氟尿嘧啶)的缓释作用研究[D].吉林:东北师范大学,2010:1-40.[18] 张建莹.5-氟尿嘧啶/壳聚糖纳米微球的制备及其药物性能评价[D].广东:暨南大学,2005:1-75.[19] 吴静,冯芳,林香春,等.羧甲基壳聚糖载药微粒的制备及其释药效能[J].中国现代医学杂志,2011,21(21):2584-2587.[20] 刘占军,张卫国,于九皋,等.负载紫杉醇壳聚糖纳米粒的制备、表征与释药性能[J].中国组织工程研究与临床康复,2009,13(3): 493-495.[21] 庞廷媛,程国华,胡泽丽.肺靶向多西紫杉醇壳聚糖微球的制备与工艺优化[J].中国药师,2011,14(3):303-307.[22] 邢志华.载阿霉素的叶酸-壳聚糖微球的制备及其体外缓释性研究[J].黑龙江大学自然科学学报,2012,29(4):511-514.[23] 柳时.叶酸偶联壳聚糖纳米粒的制备及抗肿瘤作用研究[D].湖北:华中科技大学,2006:1-49.[24] 龚金兰.肿瘤靶向性药物载体叶酸-壳聚糖微球的制备及特性研究[D].广东:南方医科大学,2008:1-47.[25] Kumar D, Tomar RS, Deolia SK, et al. Isolation and characterization of degradation impurities in epirubicin hydrochloride injection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;869(1-2):45-53. [26] McCarron PA, Woolfson AD, McCarrdrty DF, et al. Cytotoxicity of 5-fluorouracil released from a bioadhesive patch into uterine cervical tissue. Int J Pharm. 1997;151:77-86. [27] Gouvreur P, Dubernet C, Puisiuex F. Controlled drug delivery with nanoparticles, current possibilities and future trends. Eur J Pharm Biopharm. 1995;41(41):2.[28] 李亚林,徐文方.口服氟尿嘧啶类抗癌药的研究进展[J].国外医药:合成药.生化药.制剂分册,2001,22(6):323-326.[29] Rowinsky EK, Onetto N, Canetta RM, et al. Taxol: the first of the taxanes, an important new class of antitumor agents. Semin Oncol. 1992;19(6):646-662. [30] Mazzo DJ, Nguyen-Huu JJ, Pagniez S, et al. Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials. Am J Health Syst Pharm. 1997;54(5):566-569. [31] Zhang X, Burt HM, Von Hoff D, et al. An investigation of the antitumour activity and biodistribution of polymeric micellar paclitaxel. Cancer Chemother Pharmacol. 1997;40(1):81-86. [32] Weitman SD, Lark RH, Coney LR, et al. Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. 1992;52(12):3396-3401. [33] Garin-Chesa P, Campbell I, Saigo PE, et al. Trophoblast and ovarian cancer antigen LK26. Sensitivity and specificity in immunopathology and molecular identification as a folate-binding protein. Am J Pathol. 1993;142(2):557-567. [34] Toffoli G, Cernigoi C, Russo A, et al. Overexpression of folate binding protein in ovarian cancers. Int J Cancer. 1997;74(2): 193-198. [35] Kamen BA, Capdevila A. Receptor-mediated folate accumulation is regulated by the cellular folate content. Proc Natl Acad Sci U S A. 1986;83(16):5983-5987. [36] Sudimack J, Lee RJ. Targeted drug delivery via the folate receptor. Adv Drug Deliv Rev. 2000;41(2):147-162. [37] Reddy JA, Low PS. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst. 1998;15(6):587-627. |